BioCentury
ARTICLE | Clinical News

OvaRex MAb: Completed Phase II/IIb trial

September 10, 2001 7:00 AM UTC

AltaRex Corp. (TSE:AXO; ALXFF), Waltham, Mass. Product: OvaRex MAb Business: Cancer Therapeutic category: Immune stimulation, Antibody Target: CA125 Description: Murine monoclonal antibody (MAb) aga...